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Cell signaling, i.e. communication between cells, plays a fundamental 
role in the regulation of all biological processes. Paracrine signaling 
refers to signaling over a short distance between different neighboring 
cells types. Because of its importance in processes such as tissue 
repair, tissue remodeling and regeneration, the complex paracrine 
signaling networks are gaining momentum as a research topic.  
After radiation exposure paracrine signaling processes play an 
important role in normal tissue regeneration as well as in post-
irradiation aberrant wound healing. Hence, if possible, selectively 
influencing these paracrine processes could be a strategy to improve 
post-irradiation normal tissue recovery. Exogenous administration of 
certain molecules that are also being produced as paracrine 
mediators, such as keratinocyte growth factor, has been shown to 
improve post-irradiation normal tissue recovery in various models. It 
can be hypothesized that strategies that induce an autologous pro-
regenerative paracrine response which includes the release of a 
number of these stimulating factors, may be more efficient than 
administration of a single factor. Likewise, long term normal tissue 
dysfunction could be diminished by limiting pro-fibrotic paracrine 
cascades. Potential future strategies to reduce radiation injury by 
paracrine modulation include stem cell therapies as well as drugs that 
specifically affect a paracrine cascade in the organ of interest.  
Stem cell therapies are under investigation to improve post-irradiation 
functional recovery in organs such as the salivary glands, the intestine 
and the brain. Interestingly, the stimulated or injected stem cells may 
not only exert their effect by differentiation into organ specific cells, 
but also by improving vasculogenesis and producing pro-regenerative 
paracrine signals. Induction of a stimulating paracrine cascade 
appears to be one of the main mechanisms of action in various tissue 
repair models including post-irradiation models. Stem cell-mediated 
paracrine effects may be further improved by preconditioning or 
genetically modifying the stem cells. 
To date, there are no drugs to reduce radiation injury by selectively 
affecting paracrine signaling. However, the currently available drugs 
do affect various cell signaling processes including paracrine signaling. 
For example, we have shown that the radioprotective drug 
combination gamma-tocotrienol and pentoxifylline improves post-
irradiation hematopoietic recovery.  The drug combination was shown 
to induce the availability of number of a number of pro-regenerative 
cytokines in the bone marrow micro environment, indicating that 
paracrine signaling may be of importance. 
Increasing the knowledge on post-irradiation and therapy- induced 
paracrine responses is essential to develop new insights to decrease 
radiation-induced normal tissue injury. Hence, future studies should 
include adequate assays to measure the local presence or release of 
paracrine factors, as opposed to only measuring systemic effects. 
In summary, paracrine signaling plays an important role in tissue 
repair. This talk aims to provide a comprehensive overview of current 
knowledge on paracrine signaling in post-irradiation normal tissue 
recovery as well as of potential of strategies that aim to reduce 
radiation-induced organ injury by paracrine modulation.   
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Brachytherapy is indicated for both post-operative treatment 
following hysterectomy and primary treatment in medically 
inoperable cases of carcinoma of the endometrium. The indcations for 
vaginal vault brachytherapy postoperatively have been defined by the 
PORTEC trials. It is now recommended for intermediate risk disease 
based on stage IB or Grade 2 histology and with external beam 
radiotherapy for high risk disease where there has been cervical 
stromal involvement. 
The role of image guidance in vaginal vault brachytherapy is 
controversial. The technique is simple using a vaginal cylinder or in 
some units ovoids or purpose built moulds. The dosimetry is also 
simple delivering a uniform dose to the vaginal mucosa and 
submucosal lymphatics in the upper vagina. The organs at risk are well 
defined with anteriorly the bladder and posteriorly the rectum. 
Orthogonal xray films provide little useful dosimetric information 
however there has been increasing interest in the use of cross 
sectional imaging which can highlight variations in normal anatomy, 
changes with bladder filling and the effect of inadequate apposition of 
the applicator due to air bubbles or fluid along the applicator surface. 
The clinical implications of such observations remain uncertain and 
the use of cross sectional imaging for this otherwise simple technique 
varies considerably between different centres. 
In contrast, treatment of the uterus in situ for endometrial cancer 
represents a dosimetric challenge and image guidance provides vital 
information to enable optimisation of dose delivery. Modern MR 
imaging can produce accurate pretreatment evaluation of endometrial 
cancer with a high predictive value for stage. Incorporation of this 
information into the treatment algorithm greatly increases the 
accuracy of radiation delivery. Different techniques are adopted in 
this setting ranging from a single line source with an intrauterine 
tube to specialised applicators such as the Rotte Y applicator or 
Heymann's capsules. For each of these accurate definition of the CTV 
is important and this will be optimally achieved using cross sectional 
imaging with best soft tissue definition achieved with MR. Similarly 
critical organs at risk, the bladder and rectum, are best defined in 
this way to enable adaptive planning and dosimetry incorporating 
normal tissue constraints to be achieved. 
Reproducability and the need for repeated imaging will always be an 
uncertainty in image guided brachytherapy and this is as relevant to 
endometrial brachytherapy as other sites. Positioning and fixation of 
the vaginal cylinder during imaging may vary from that during 
treatment so that dose calculations do not accurately reflect the 
situation during treatment. The use of intrauterine applicators may 
minimise uterine movement when treating in situ endometrial cancer 
but bladder and rectum may change considerably over a few hours 
and between daily fractions.  
Despite this cross sectional image guided brachytherapy 
for endometrial cancer in situ should now be the standard of care; its 
role in postoperative teatment remains under evaluation.   
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The target concept of image guided adaptive brachytherapy (IGABT) 
has dramatically improved the clinical outcome in cervical cancer 
regarding both local control and late morbidity. The GEC ESTRO target 
concept used with IGABT is 4D as it incorporates both tumour volume 
(3D) at diagnosis – the Intermediate Risk Clinical Target Volume (IR 
CTV) and later at time of BT (4D) – the High Risk Clinical Target 
Volume (HR CTV), when significant tumour regression often has been 
obtained by preceding external beam radiotherapy (EBRT) and 
concomitant chemotherapy. IGABT is already being used as a routine 
procedure in several institutions, but the majority of centres are just 
leaving 2D radiographic based BT. These changes in clinical practice 
are reflected in a new ICRU report to replace ICRU38 and expected to 
be published this year. The aim of this presentation is to review some 
of the challenges and pitfalls which both new and experienced users 
of IGABT in cervical cancer are facing to day.  
Evidently accurate target delineation is critical. Quite large inter-
observer variation may be observed especially among new users of the 
IGABT which may lead to unreliable DVH parameters, not appropriate 
application techniques, insufficient target coverage and potentially 
loss of local control. Especially the “grey zones” in the direction of 
the parametria require training to be interpreted correctly in relation 
to the HR CTV and IR CTV boundaries. In view of the steep dose 
gradients involved in BT also the organs at risk (OAR) require 
meticulous contouring. Case audit, contouring workshops, specific 
courses and participation in multicentre studies are ways to reduce 
this variability. For treatment planning a conservative approach is 
advocated using a classical pear shaped dose distribution as starting 
point in the optimisation process and not conforming too tight to the 
HR CTV unless forced by presence of near by OAR. A pitfall in this 
context is the “softness” of the DVH constraints for OAR in the sense 
that estimation of the dose accumulation assumes a scenario in which 
the same part of a given OAR are supposed repetitively hit by the 
highest dose. 
When switching to IGABT it is important to focus on the way BT and 
EBRT are combined. A major requirement for treatment planning and 
optimisation in IGABT is the ability to add up EBRT and BT doses by 
use of equivalent dose in 2 Gy (EQD2) calculations. This require that 
HR CTV, IR CTV and the small volumes (D0.1cm³ and D2cm³) of OAR 
